Delisting riskPopularity #4,761
Xtant Medical (XTNT)
Supplies orthobiologics, spine implants, and U.S. surgical-hemostasis products.
$0.3600
After hours+0.00 (+1.12%)
At close$0.3560(+5.64%)
In millions of USD, except per-share figures
| In millions | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 28 | 28 | 30 | 28 | 32 | 33 | 35 | 33 | 32 | 21 | 23 |
| Cost of revenue | 11 | 11 | 11 | 12 | 15 | 13 | 11 | 11 | 15 | 9 | 10 |
| Gross profit | 17 | 17 | 19 | 16 | 16 | 20 | 24 | 22 | 18 | 12 | 13 |
| 21 | 21 | 22 | 20 | 18 | 19 | 20 | 19 | 19 | 15 | 22 | |
| Research & development | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 1 |
| 20 | 20 | 21 | 19 | 17 | 19 | 19 | 19 | 18 | 14 | 17 | |
| Selling & marketing | 12 | 12 | 13 | 12 | 12 | 11 | 12 | 12 | 11 | 8 | 10 |
| General & administrative | 9 | 8 | 8 | 7 | 6 | 8 | 7 | 7 | 7 | 6 | 6 |
| Other expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 |
| Operating income | −4 | −3 | −3 | −4 | −2 | 1 | 5 | 3 | −1 | −3 | −9 |
| 0 | −1 | −1 | −1 | −1 | −1 | −1 | −1 | 3 | 0 | 0 | |
| Interest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest expense | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Other non-operating income | −1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | −3 | 0 | 0 |
| Income before tax | −4 | −4 | −4 | −5 | −3 | 0 | 4 | 2 | 2 | −3 | −9 |
| Income tax expense | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 |
| Net income from continuing operations | −4 | −4 | −4 | −5 | −3 | 0 | 4 | 1 | 0 | −3 | −9 |
| Net income | −4 | −4 | −4 | −5 | −3 | 0 | 4 | 1 | 0 | −3 | −9 |
| EPS, basic | −$0.03 | −$0.03 | −$0.03 | −$0.04 | −$0.02 | $0.00 | $0.03 | $0.01 | $0.00 | −$0.02 | −$0.07 |
| EPS, diluted | −$0.03 | −$0.03 | −$0.03 | −$0.04 | −$0.02 | $0.00 | $0.02 | $0.01 | $0.00 | −$0.02 | −$0.07 |
| Weighted average shares, basic | 130 | 130 | 130 | 135 | 139 | 143 | 139 | 139 | 140 | 140 | 140 |
| Weighted average shares, diluted | 130 | 130 | 130 | 135 | 139 | 143 | 149 | 149 | 150 | 150 | 140 |
| EBITDA | −2 | −2 | −2 | −3 | −1 | 2 | 6 | 4 | 4 | −2 | −8 |
| Depreciation & amortization | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 |
| EBIT | −3 | −3 | −3 | −4 | −2 | 1 | 5 | 2 | 2 | −2 | −9 |